DTP Branches and Offices
Provides planning, implementation and oversight for all DTP activities, including participation in the NCI Experimental Therapeutics (NExT).
PTGB resides in a unique situation in relation to the extramural grant community and DTP’s drug discovery and development activities. Through management of a large grant and cooperative agreement portfolio, PTGB staff maintains extensive interactions with the external research community and can provide advice to foster DTP’s drug discovery mandate.
Runs the classical NCI60 cell line screen as a service available to the global cancer community where investigators can submit compounds and biologics for testing in this well validated resource. MPB can also provide investigators with frozen pellets, DNA and RNA from the NCI60 cell lines for their specific studies.
Operates at Frederick (NCI-Frederick), providing budgetary oversight and technical direction for an extensive contractual effort designed to discover chemotherapeutic agents for cancer, including in vivo study model development and screening, distribution of experimental animal and human tumor cell lines, production and distribution of genetically and biologically defined rodents.
The primary responsibility of T&PB is to obtain the toxicology and pharmacology data necessary for NCI to file an Investigational New Drug (IND) application with the FDA in order to conduct Phase I clinical trials of new oncolytic agents in humans.
Provides worldwide scientific liaison activities with universities and industries to stimulate the submission of a wide variety of synthetic compounds, and pure natural products for in vitro anti-cancer screening; management of the storage, inventory, documentation, synthesis, acquisition and distribution of chemical samples for research purposes to NIH and external investigators.
Responsible for the acquisition and distribution of crude natural product materials from terrestrial and marine environments worldwide, and oversights the operations of the Natural Products Repository and the Natural Products Extraction Laboratory.
Provide oversight of the Biopharmaceutical Development Program (BDP) at the National Cancer Institute Frederick campus (NCI-Frederick), which produces a variety of biopharmaceuticals under current Good Manufacturing Practices (cGMP) for Phase I/II human clinical trials or advanced preclinical animal testing. BRB also oversees a biological Preclinical Repository for the distribution of cytokines, monoclonal antibodies, and a grant program in the area of biological agents, immunological concepts, and animal models for cancer treatment.
Provides the clinical research community with high-quality and well-characterized chemical substances and drug products. Whenever possible, USP/NF grade excipients with a proven track record for consistency and safety are used. The clinical supplies PRB provides are guaranteed to meet or exceed FDA accepted potency and purity requirements while in use.
Manages the chemical and biological databases to support DTP’s ongoing research efforts. ITB employs state-of-art software and hardware facilities to provide support for DTP and engages in collaborative research to promote further implementation of information technology within the branch.